Literature DB >> 2786672

Epidermal growth factor in the gastroprotective and ulcer-healing actions of sucralfate in rats.

S J Konturek1, T Brozozowski, W Bielanski, Z Warzecha, D Drozdowicz.   

Abstract

Sucralfate exhibits gastroprotective properties in laboratory animals and enhances the healing of chronic gastroduodenal ulcers, but the mechanisms of these actions have not been entirely elucidated. The present study was designed to determine whether or not epidermal growth factor (EGF), which also has gastroprotective and ulcer-healing properties, contributes to the action of sucralfate in rat stomach. It was confirmed that sucralfate, like 16,16-dimethyl prostaglandin E2, protects the gastric mucosa against ethanol damage and increases mucosal generation of prostaglandins. Removal of the endogenous source of EGF (sialoadenectomy) did not abolish the protective and prostaglandin-stimulating effects of sucralfate. Exogenous EGF and 16,16-dimethyl prostaglandin E2 were also protective in rats with intact and removed salivary glands. Sucralfate, like EGF, enhanced the healing of chronic gastric and duodenal ulcerations induced by serosal application of acetic acid. Sucralfate was found to bind EGF in a pH-dependent manner and to accumulate it in ulcer areas. Thus, the peptide is available locally in high concentrations to accelerate tissue repair and the healing process in ulcerated mucosa. The ulcer-healing effects of sucralfate were reduced with sialoadenectomy and partially restored with oral administration of EGF. It was concluded that EGF is not essential for the gastroprotection induced by sucralfate, but seems to play an important role in the ulcer-healing action of this drug.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786672     DOI: 10.1016/0002-9343(89)90154-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

1.  Effect of long-term sucralfate ingestion on antral and fundic epithelial proliferation in the rat.

Authors:  H Kuwayama
Journal:  Dig Dis Sci       Date:  1996-05       Impact factor: 3.199

2.  Radiodermatitis prevention with sucralfate in breast cancer: fundamental and clinical studies.

Authors:  Sabrina Falkowski; Patrick Trouillas; Jean-Luc Duroux; Jean-Marie Bonnetblanc; Pierre Clavère
Journal:  Support Care Cancer       Date:  2009-12-09       Impact factor: 3.603

3.  Comparison of topical sucralfate with dexpanthenol in rat wound model.

Authors:  Eda Yildizhan; Burak Veli Ulger; Murat Akkus; Dilara Akinci; Omer Basol
Journal:  Int J Exp Pathol       Date:  2022-04-20       Impact factor: 2.793

4.  Transforming growth factor alpha protection against drug-induced injury to the rat gastric mucosa in vivo.

Authors:  M Romano; W H Polk; J A Awad; C L Arteaga; L B Nanney; M J Wargovich; E R Kraus; C R Boland; R J Coffey
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

5.  Fibroblast growth factor in gastroprotection and ulcer healing: interaction with sucralfate.

Authors:  S J Konturek; T Brzozowski; J Majka; A Szlachcic; W Bielanski; J Stachura; W Otto
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

6.  Sucralfate gel as a radioprotector against radiation induced dermatitis in a hypo-fractionated schedule: a non-randomized study.

Authors:  V Kouloulias; C Asimakopoulos; M Tolia; G Filippou; K Platoni; M Dilvoi; I Beli; J Georgakopoulos; G Patatoukas; N Kelekis
Journal:  Hippokratia       Date:  2013-04       Impact factor: 0.471

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.